<code id='9FD37ADE9F'></code><style id='9FD37ADE9F'></style>
    • <acronym id='9FD37ADE9F'></acronym>
      <center id='9FD37ADE9F'><center id='9FD37ADE9F'><tfoot id='9FD37ADE9F'></tfoot></center><abbr id='9FD37ADE9F'><dir id='9FD37ADE9F'><tfoot id='9FD37ADE9F'></tfoot><noframes id='9FD37ADE9F'>

    • <optgroup id='9FD37ADE9F'><strike id='9FD37ADE9F'><sup id='9FD37ADE9F'></sup></strike><code id='9FD37ADE9F'></code></optgroup>
        1. <b id='9FD37ADE9F'><label id='9FD37ADE9F'><select id='9FD37ADE9F'><dt id='9FD37ADE9F'><span id='9FD37ADE9F'></span></dt></select></label></b><u id='9FD37ADE9F'></u>
          <i id='9FD37ADE9F'><strike id='9FD37ADE9F'><tt id='9FD37ADE9F'><pre id='9FD37ADE9F'></pre></tt></strike></i>

          Home / hotspot / knowledge

          knowledge


          knowledge

          author:Wikipedia    Page View:83322

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In